KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 105 filers reported holding KEROS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,284 | -4.6% | 2,236 | +20.3% | 0.00% | 0.0% |
| Q2 2023 | $74,695 | +24.0% | 1,859 | +31.8% | 0.00% | +50.0% |
| Q1 2023 | $60,250 | -16.8% | 1,411 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $72,455 | +36.7% | 1,411 | 0.0% | 0.00% | +50.0% |
| Q3 2022 | $53,000 | +76.7% | 1,411 | +29.2% | 0.00% | +100.0% |
| Q2 2022 | $30,000 | -49.2% | 1,092 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $59,000 | -7.8% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $64,000 | +48.8% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $43,000 | -6.5% | 1,092 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $46,000 | -31.3% | 1,092 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $67,000 | -13.0% | 1,092 | 0.0% | 0.00% | -25.0% |
| Q4 2020 | $77,000 | +220.8% | 1,092 | +77.6% | 0.00% | +300.0% |
| Q3 2020 | $24,000 | +4.3% | 615 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $23,000 | – | 615 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |